The Australia Veterinary Pharmaceuticals Market was valued at $394.7 Million in 2026 and projected to reach to $550.1 Million by 2031, representing a compound annual growth rate of 6.9%. Australia's veterinary pharmaceuticals market is positioned for sustained growth through 2031, with a CAGR of 6.9% outpacing the global average of 6.3%.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia's veterinary pharmaceuticals market is valued at USD 394.7 million in 2026 and is projected to reach USD 550.1 million by 2031, demonstrating robust expansion driven by increasing animal health awareness.
Australia's growing pet ownership rates are driving demand for companion animal pharmaceuticals, with pet owners increasingly investing in preventive care and treatment options for their animals.
The Australian agricultural sector's focus on livestock health and disease prevention is fueling demand for veterinary pharmaceuticals, particularly in cattle, sheep, and poultry farming operations.
Australia's stringent regulatory framework through the APVMA (Australian Pesticides and Veterinary Medicines Authority) ensures high-quality pharmaceutical standards, supporting market credibility and consumer trust.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | ONLINE PHARMACIES/E-COMMERCE (Distribution Channel) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 6.3% from 2026 to 2031 |
| Largest Segment | COMPANION ANIMALS (Animal Type) |
| Market Size Base Year (Billions) | ~USD 29.01 (2026) |
| Revenue Forecast (Billions) | ~USD 39.37 (2031) |
| Segments Covered | Product Type, Type, Route Of Administration, Formulation Type, Indication, Animal Type, Distribution Channel, End User |
8 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ZOETIS INC. | United States | Public Company | Companion animal therapeutics (parasiticides, dermatology, pain, other pharma),Livestock pharmaceuticals (vaccines, anti-infectives, other pharma),Diagnostics (point-of-care, instruments, reagents, reference labs), |
| MERCK & CO., INC | United States | Public Company | Oncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Cardiovascular, pulmonary hypertension, and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, Prevymis, Bridion, Dificid, Zerbaxa), |
| ELANCO ANIMAL HEALTH INCORPORATED | United States | Public Company | Companion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal family),Companion animal vaccines and therapeutics (including Galliprant and vaccines portfolio),Cattle products (Rumensin, Baytril, Experior and related medicated feed additives, injectables, vaccines), |
| VIRBAC | France | Public Company | Companion animal therapeutics (vaccines, antibiotics, anti-inflammatories, dermatology, dental, specialty),Parasiticides (incl. collars like Prevexto),Farm animal vaccines (incl. Suigen Entero 3, PCV2, Donoban), |
| CEVA | United States | Public Company | 5G/5G-A baseband DSP and RAN IP (PentaG-RAN, XC20/XC21/XC23, Ceva-BX2),Connectivity IP (Ceva-Waves Bluetooth, Wi-Fi, UWB, Links, DragonFly NB-IoT),Sensing, audio, and spatial software IP (SensPro, BX1, ClearVox, RealSpace, MotionEngine), |
| VETOQUINOL | France | Public Company | Companion animal therapeutics (mobility, pain, dermatology, behavior, internal medicine, cardio-nephrology),Livestock therapeutics (udder health, antibiotics, reproduction, internal medicine),Antiparasitics (companion and livestock), |
| DECHRA PHARMACEUTICALS PLC | United Kingdom | Private Company | Companion animal therapeutics,Food-producing animal products,Equine therapies, |
| HESTER BIOSCIENCES LIMITED | India | Public Company | Poultry vaccines,Large animal vaccines,Veterinary pharmaceuticals (therapeutics), |
| ANIMALCARE GROUP PLC | United Kingdom | Public Company | Companion animal pharmaceuticals (pain, endocrine, chronic care),Dental and joint health (Orozyme, Plaqtiv+, Cosequin),Equine pharmaceuticals and supplements, |
Zoetis Inc. is a United States-based public company founded in 2012 that employs 14,500 people. The company operates in the animal health sector.
Merck & Co., Inc. is a United States-based public company founded in 1891 with 74,000 employees. The company is a major pharmaceutical and healthcare organization.
Elanco Animal Health Incorporated is a United States-based public company founded in 1954 with 9,650 employees. The company specializes in animal health products and services.
Virbac is a French public company founded in 1968 with 6,442 employees. The company operates in the animal health and veterinary pharmaceutical sector.
Ceva is a United States-based public company founded in 1999 with 400 employees. The company operates in the animal health industry.
Vetoquinol is a French public company founded in 1933 with 2,454 employees. The company specializes in veterinary pharmaceuticals and animal health products.
Dechra Pharmaceuticals PLC is a United Kingdom-based private company founded in 1997 with 2,457 employees. The company operates in the veterinary pharmaceutical sector.
Hester Biosciences Limited is an India-based public company founded in 1987. The company operates in the animal health and veterinary pharmaceutical sector.
Animalcare Group PLC is a United Kingdom-based public company with 220 employees. The company operates in the animal health and veterinary pharmaceutical industry.
Australia's veterinary pharmaceuticals market is valued at USD 394.7 million in 2026.
Australia's veterinary pharmaceuticals market is projected to reach USD 550.1 million by 2031.
Australia's veterinary pharmaceuticals market is growing at a CAGR of 6.9% from 2026 to 2031.
Australia's CAGR of 6.9% outpaces the global average of 6.3%, indicating stronger regional market momentum.
Key drivers include rising pet ownership, livestock disease management, zoonotic disease awareness, and regulatory support for veterinary innovation in Australia.
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the Veterinary Pharmaceuticals Market. It was also used to obtain important information about the key players, market classification, and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the Veterinary Pharmaceuticals Markets. Primary sources from the demand side include healthcare professionals from hospitals, ambulatory surgical centers, long-term care facilities, diagnostic imaging centers, outpatient clinics, and other end users.
A breakdown of the primary respondents is provided below:

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other Designations include sales managers, marketing managers, and product managers.
Note 3: Tiers are defined based on a company’s total revenue as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The total size of the veterinary pharmaceuticals market was determined through data triangulation across three approaches, as outlined below. After each approach, the weighted average of the three was calculated based on the level of assumptions used in each.

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed where applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in the market engineering process.
The veterinary pharmaceuticals market comprises medicinal products used to prevent, control, and treat diseases in animals, excluding vaccines. It includes therapeutic drug classes such as anti-infectives (antibacterials, antivirals, antifungals, antiparasitic), anti-inflammatory drugs, hormonal therapies, dermatological drugs, cardiovascular drugs, gastrointestinal agents, and other prescription and over-the-counter pharmaceuticals. These products address indications including infectious diseases, dermatological disorders, reproductive health, metabolic diseases, and pain management, among others. The market covers both companion and livestock animals and is supplied through veterinary hospitals, clinics, pharmacies, and animal health distribution channels globally.
Full forecast, segment splits, and company analysis for all Veterinary Pharmaceuticals Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report